Oil exports through the Strait of Hormuz have increased, helping to lower oil prices with Goldman Sachs forecasting Brent crude to moderate to $85 per barrel by year-end. However, Europe faces a looming natural gas shortage due to record-breaking summer heat and depleted storage levels, despite stable supply largely supported by U.S. LNG exports. European reliance on U.S. and Russian LNG continues amid geopolitical tensions, with prices expected to remain high through winter. Energy firms like BP and TotalEnergies are recommended buys as they benefit from higher natural gas prices and oil discoveries, signaling potential growth despite ongoing market uncertainties.
Europe's winter energy crunch is the subject, with Pluang's energy sector data providing context. As of Oct 02, 2026 03:26 WIB, 21 of 38 energy-sector US stocks on Pluang rose while 17 fell. Notable prices include ConocoPhillips at USD 127.06 with a 1-day change of +1.53%, Ecopetrol SA at USD 16.23 down 1.49%, and TotalEnergies SE at USD 85.55 down 1.45%.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
